<DOC>
	<DOC>NCT02534753</DOC>
	<brief_summary>This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.</brief_summary>
	<brief_title>A Pharmacokinetics Study of Intravenous Ascorbic Acid</brief_title>
	<detailed_description>The objectives of this study are: 1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV). 2. To evaluate the safety and tolerability of AA administered intravenously.</detailed_description>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Is between the ages of 18 and 45 years, inclusive. Has a body mass index (BMI) between 18 and 32 kg/m2. Of sound health and has the ability to understand the requirements of the study and is willing to comply with all study requirements and procedures. Participates in activities that would not allow accurate evaluation of the pharmacokinetics of Ascorbic Acid Medical or physical conditions that would not allow safe participation and/or accurate evaluation of the pharmacokinetics of Ascorbic Acid Has participated in an investigational drug study within the 30 days prior to CRU admission.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>